Drug intelligence / Profile preview

BF-223

Development stage: Preclinical
Lead developer: BullFrog AI
Modality: Small Molecules
Administration: Oral

Overview

BF-223 is a **novel small molecule prodrug of mebendazole** developed by BullFrog AI for the treatment of glioblastoma and potentially other neoplasms affecting the nervous system. Preclinical studies demonstrate improved solubility and bioavailability relative to prior mebendazole formulations and show statistically significant antitumor effects and survival benefits in glioblastoma animal models. BF-223 is designed to improve pharmacologic properties (e.g., absorption, distribution) of mebendazole to enhance its therapeutic potential against **glioblastoma**, a highly aggressive brain tumor with limited treatment options[1][4][8][10][6].

Other names: prodrug of mebendazole

Targets

TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on BF-223.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BF-223.

Explore the full profile